Nanohale AG (ETR:FYB) | WebDisclosure

Basculer en Français

9480	Companies
185543	Keywords
117939	Articles
99384	Press releases

Home
Companies
Nanohale AG

PRESS RELEASE

published on 07/26/2024 at 12:00, 1 year 4 months ago

Formycon and Fresenius Kabi receive positive CHMP opinion for FYB202 (Ustekinumab), a biosimilar candidate to Stelara®
Formycon and Fresenius Kabi receive positive CHMP opinion for FYB202 biosimilar candidate to Stelara. Approval expected in early Q4 2024. Biosimilars boost healthcare access & reduce costs globally

Biosimilar Formycon Fresenius Kabi FYB202 CHMP Opinion
BRIEF

published on 07/26/2024 at 10:59, 1 year 4 months ago

FYB202 Biosimilar to Stelara Receives Positive CHMP Opinion from EMA

Biosimilar Formycon FYB202 CHMP EMA
BRIEF

published on 07/26/2024 at 10:59, 1 year 4 months ago

Le biosimilaire FYB202 de Stelara reçoit un avis positif du CHMP de l'EMA

Formycon FYB202 Biosimilaire CHMP EMA
PRESS RELEASE

published on 07/26/2024 at 10:54, 1 year 4 months ago

EQS-Adhoc: Stelara® Biosimilar Candidate FYB202 (Ustekinumab) receives positive CHMP opinion from EMA
Formycon AG's biosimilar candidate FYB202 (Ustekinumab) for Stelara® receives a positive opinion from EMA's CHMP, recommended for EU approval for treating severe inflammatory diseases

Formycon AG Biosimilar FYB202 CHMP EMA
BRIEF

published on 07/01/2024 at 06:55, 1 year 5 months ago

Formycon Receives FDA Approval for Aflibercept Biosimilar

FDA Approval Biosimilar Formycon Retinal Diseases Ophthalmic Therapies
BRIEF

published on 07/01/2024 at 06:55, 1 year 5 months ago

Formycon reçoit l'approbation de la FDA pour le biosimilaire Aflibercept

Approbation De La FDA Formycon Biosimilaire Maladies De La Rétine Thérapies Ophtalmiques
PRESS RELEASE

published on 07/01/2024 at 06:50, 1 year 5 months ago

Formycon receives FDA approval for FYB203/AHZANTIVE®1) (aflibercept-mrbb), a biosimilar to Eylea®2)
Formycon receives FDA approval for FYB203/AHZANTIVE(R) (aflibercept-mrbb), a biosimilar to Eylea(R). The approval highlights Formycon's expertise and commitment to providing effective and affordable biosimilar therapies for retinal diseases.

FDA Approval Biosimilar Formycon Eylea Retinal Diseases
BRIEF

published on 06/28/2024 at 23:55, 1 year 5 months ago

FDA Approves Biosimilar FYB203/AHZANTIVE® for Retinal Diseases

FDA Approval Biosimilar Eylea Retinal Diseases Treatment Approval
BRIEF

published on 06/28/2024 at 23:55, 1 year 5 months ago

La FDA approuve le biosimilaire FYB203/AHZANTIVE® pour les maladies rétiniennes

Approbation De La FDA Biosimilaire Eylea Maladies De La Rétine Approbation Du Traitement
PRESS RELEASE

published on 06/28/2024 at 23:50, 1 year 5 months ago

EQS-Adhoc: FDA grants approval for Eylea®1) biosimilar FYB203/AHZANTIVE®2) (aflibercept-mrbb)
FDA grants approval for Eylea biosimilar FYB203/AHZANTIVE by Formycon AG and Klinge Biopharma GmbH. Biosimilar approved for nAMD and other retinal diseases

FDA Approval Retinal Diseases Eylea Biosimilar FYB203/AHZANTIVE Neovascular Age-Related Macular Degeneration

Accesswire

Published on 12/05/2025 at 20:25, 16 minutes ago

The Feedback Loop: Why SMX's Adoption in One Industry Accelerates Interest in All the Others
Published on 12/05/2025 at 20:15, 26 minutes ago

When Proof Becomes Infrastructure, Markets Rewrite the Story (NASDAQ: SMX)
Published on 12/05/2025 at 19:50, 51 minutes ago

Gold, Rare Earth Minerals, Digital Assets: The Market Just Realized SMX Sits in All Three
Published on 12/05/2025 at 19:20, 1 hour 21 minutes ago

The Multi-Sector Validation Shock: Why SMX Became Impossible for Markets to Ignore
Published on 12/05/2025 at 18:45, 1 hour 56 minutes ago

Four Global Markets, One Engine: SMX Just Redefined What a Supply Chain Can Prove

View all ACCESSWIRE

EQS Group

Published on 12/05/2025 at 18:58, 1 hour 43 minutes ago

EQS-Adhoc: HORNBACH Holding AG & Co. KGaA: Reduced earnings in Q3 2025/26 – Guidance for adjusted EBIT at previous year’s level still valid
Published on 12/05/2025 at 18:26, 2 hours 15 minutes ago

POS-Transaction in Own Shares
Published on 12/05/2025 at 18:15, 2 hours 26 minutes ago

Completion of merger to form Helvetia Baloise Holding Ltd
Published on 12/05/2025 at 17:51, 2 hours 49 minutes ago

Issue of Equity
Published on 12/05/2025 at 17:46, 2 hours 55 minutes ago

Booster Precision Components Holding GmbH announces the successful completion of its Written Procedure to amend and waive certain terms under the terms and conditions of the Bonds

Les Echos

Published on 12/05/2025 at 17:18, 3 hours 23 minutes ago

La vidéo de la réunion de présentation des résultats 2024-2025 du 5 décembre 2025 est disponible
Published on 12/05/2025 at 17:18, 3 hours 23 minutes ago

The video of the 2024-2025 results presentation meeting on December 5, 2025, is available
Published on 12/05/2025 at 15:10, 5 hours 30 minutes ago

Mersen: Number of shares and voting rights as of November 30, 2025
Published on 12/05/2025 at 15:10, 5 hours 30 minutes ago

Mersen : nombre d'actions et de droits de vote au 30 novembre 2025
Published on 12/05/2025 at 13:58, 6 hours 43 minutes ago

RELATIF A LA MISE A DISPOSITION DU PUBLIC DE LA NOTE D'INFORMATION ET DES INFORMATIONS RELATIVES AUX CARACTERISTIQUES, NOTAMMENT JURIDIQUES, FINANCIERES ET COMPTABLES DE LEGRAND FRANCE

View all LES ECHOS COMFI WIRE